16 Dec COVID-19: Antibody Response to Vaccination Decreases with Time
MedicalResearch.com Interview with:
Shuchi Anand, MD MS (she/her)
Assistant Professor in Medicine
Director, Center for Tubulointerstitial Kidney Disease
Stanford University School of Medicine
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: A majority of people on dialysis who completed vaccination as of September 2021 have had a decline in antibody response to levels that would render them vulnerable to infection. Antibody response immediately after vaccination and circulating antibody response is strongly associated with risk for breakthrough after the initial vaccination series.
MedicalResearch.com: What should readers take away from your report?
Response: Circulating antibodies are one important measure of risk for breakthrough infection.
MedicalResearch.com: What recommendations do you have for future research as a result of this work?
Response: People on dialysis, people with other chronic conditions should get booster doses. Future research could determine if knowing your antibody response could increase booster uptake.
Disclosures: Ascend Clinical lab funded the remainder plasma testing for this study.
Shuchi Anand, Maria E. Montez-Rath, Jialin Han, et al. SARS-CoV-2 Vaccine Antibody Response and Breakthrough Infection in Patients Receiving Dialysis. Ann Intern Med. [Epub ahead of print 14 December 2021]. doi:10.7326/M21-4176
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on December 16, 2021 by Marie Benz MD FAAD